Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
4.570
-0.660 (-12.62%)
Jun 9, 2026, 1:41 PM EDT - Market open
Bluejay Diagnostics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
4.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 249.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beyond Air | 6.92M |
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.91M |
| ENvue Medical | 2.18M |
| Catheter Precision | 1.11M |
| Sintx Technologies | 1.03M |
| HeartSciences | 8.67K |
BJDX News
- 3 days ago - Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 7 days ago - Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 days ago - Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today? - TipRanks
- 7 days ago - Bluejay Diagnostics, Argonaut Manufacturing Services announce partnership - TheFly
- 7 days ago - Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership - GlobeNewsWire
- 4 weeks ago - Bluejay Diagnostics Provides First Quarter 2026 Corporate Update - GlobeNewsWire
- 2 months ago - Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial - TheFly
- 2 months ago - Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial - GlobeNewsWire